A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Kadry, Ashraf A.
- Lacking of Efflux Mechanism in Clinical Isolate of Pseudomonas aerupinosa highly Resistant to β-Lactams and Imimnem
Authors
1 Microbiology Division. Faculty of Pharmacy. King Saud University. Riyadh, SA
Source
Scientia Pharmaceutica, Vol 71, No 2 (2003), Pagination: 89-100Abstract
In this investigation, the isolate of Pseudomonas aeruginosa from cystic fibrosis was highly resistant to β-lactarns and β-lactamase inhibitors. The resistant determinants of clinical isolate to imipenem, ceftazidime, ceftriaxone and cefepime were conjugally non-transfer. The slow or non-enzymatically mediated breakdown of imipenem and other broad spectrum β-lactams suggest the resistance of P. aeruginosa isolate to these drugs might be attributed to either permeability or efflux. Impaired penetration of imipenem and other β-lactams through the membrane was detected by a diminished expression of outer membrane (OM) proteins of approximate weight of 46 and 39 Kdal, matched to Opr D and Opr F, respectively. Efflux resistance mechanism for meropenem and β-lactams has been ruled out since the isolate failed to express outer membrane protein of about 50 Kdal, which is matched to Opr M protein channel. Thus, reduced permeability in the clinical isolate may be the main mechanism conferring resistance against β-lactarns including imipenem.Keywords
P. aeruginosac, Imipenem, β-lactams, Resistance, Permeability Barriers, Lacking Efflux, β-lactamase.
References
- Nakae T, Nakajima A, Ono T, Saito K, Yoneyama H . Resistance to β-lactam antibiotics in P.aeruginosa due to interplay between the Mex AB-OprM efflux pump and β-lactamase. Antimicrob Agents Chemother 1999; 43: 1301-1303.
- Chen HY, Yuan M, Ibrahim-Elmaghoul IB, Livermore DM. National survey of susceptibility to antimicrobials amongst clinical isolates of P. aeruginosa. J Antimicrob Chemother 1995; 35: 521-534.
- Kohler T, Hamzehpour MM, Epp SF, Pechere JC. Carbapenem activities again P. aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agenl Chemother 1999; 43: 424-427.
- Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001; 47: 247-250.
- Pagani L, Landini P, Luzzaro F, Debiaggi M, Romero E. Emergence of crossresistance to imipenem and other β-lactam antibiotics in P. aeruginosa during therapy. Microbiologica 1990; 13: 43-53.
- Hupkova M, Blahova J, Babalova M, Krcmery V, Schafer V. Transferable resistance to imipenem in Hospital isolates of P. aeruginosa. J Chemother 1993; 5: 14-16.
- Knothe H, Antal M, Krcmery V. Imipenem and ceftazidime resistance in P. aeruginosa and K. pneumoniae. J Antimicrob Chemother 1987; 19: 136-138.
- (81 Kiska DL , Gilligan PH, editors. Pseudomonas. In: Manual of clinical microbiology. 7th ed.. Murry PR, Baron EJ, Pfaller MA, Tenover FC,Yolken RH. (eds), Washington,DC: American Society for Microbiology 1999: 517-525.
- National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial disk susceptibility tests. And Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Document M2-A7 and M7-A5. January 2000; Pennsylvania, USA.
- Li XZ, Zhang L, Poole K. Interplay between the MexAB OprM multidmg efflux system and the outer membrane barrier in the multiple antibiotic resistance of P. aeruginosa. J Antimicrob Chemother 2000; 45: 433-436.
- Krcmery V, Lesicka M, Blahova J, Schafer V. Indirect transfer of resistance to imipenem in a strain of P. aeruginosa. J Chemother 1991; 3: 363-368.
- Arret B, Johnson DP, Kirshbaraum A. Outline of details of microbiological assays of antibiotics: second revision. J Pharm Sci 1971; 60: 1689-1694.
- Giordano A, Magni A, Trancassini M, Cipriani P. Outer membrane of proteins and lipopolysaccharide changes after exposure of P. aeruginosa to antibacterial drugs. Microbiologica 1993; 16: 281-286.
- Nikaido H. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 1994; 264: 382-387.
- Buscher KH, Cullmann W, Opferkuch W. Resistance of P. aeruginosa to imipenem is independent of β-lactamase production. J Antimicrob Chemother 1987a; 19: 699-706.
- Nikaido H. Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33: 1831-1836.
- Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?. Clin Infect Dis 2002; 34: 634-640.
- Yoneyama H, Nakae T. Cloning of the protein D2 gene of P. aeruginosa and its functional expression in the imipenem-resistant host. FEBS Letters 1991; 283: 177-179.
- Buscher KH, Cullmann W, Dick W, Opferkuch W. Imipenem resistance in P. aeruginosa resulting from diminished Expression of an outer membrane protein. Antimicrob Agents Chemother 1987b; 31: 703-708.
- Pedersen SS, Pressler T, Hoiby N, Bentzon MW, Koch C. Imipenem/cilastatin treatment of multiresistant P. aeruginosa lung infection in cystic fibrosis. J Antimicrob Chemother 1985; 16:629-635.
- Srikumar R, Li XZ, Poole K . Inner membrane efflux components are responsible for β-lactarn specificity of multidrug efflux pumps in P. aeruginosa. J Bacterial 1997; 179: 7875-788.
- Maseda H, Yoneyama H, Nakae T Assignment of the substrate-selective subunits of the Mex EF-OprN multidrug efflux pump of P. aeruginosa Antimicrob Agents Chemother 2000; 44: 658-664.
- Masuda N, Sakagawa E, Ohya S . Outer membrane proteins responsible for multiple drug resistance in P. aeruginosa Antimicrob Agents Chemother 1995; 39: 645-649.
- Resistance of Escherichia coli and Klebsiella pneumoniae Isolated from different Sources to β-Lactam Antibiotics
Authors
1 Department of Microbiology and Immunology, Zagazig University, Zagazig, EG
2 Department of Microbiology and Biotechnology, Delta University for Science and Technology, Gamasa, Mansoura, EG
Source
Research Journal of Pharmacy and Technology, Vol 10, No 2 (2017), Pagination: 589-591Abstract
Escherichia coli and Klebsiella pneumoniae are important human pathogens that cause many infectious diseases. β-lactam antibiotics are commonly used in the treatment of these infections. However, resistance to such antibiotics complicates the treatment. Mechanisms of resistance to β-lactams include production of β-lactamases, efflux pumps, change in drug targets and outer membrane impermeability. This study was performed to investigate the resistance of Klebsiella pneumoniae and Escherichia coli to β-lactam antibiotics. The study was carried out from May 2014 to May 2015. Five hundred clinical isolates were collected from patients in Belquas Hospital and Mansoura University Hospitals. Three hundred isolates were identified as Klebsiella pneumoniae and Escherichia coli (one hundred and fifty isolates each). Klebsiella pneumoniae and Escherichia coli isolates showed high resistance to cefoperazone and ceftriaxone, intermediate resistance to cefoxitin, cefotaxime, ceftazidime and amoxicillin-clavulanic acid and low resistance to imipenem and meropenem. Klebsiella pneumoniae showed more resistance than Escherichia coli. Resistance of Klebsiella pneumoniae was higher to cefoperazone, ceftriaxone, ceftazidime, imipenem and meropenem. However, Escherichia coli was more resistant to cefotaxime and cefoxitin. The resistance to amoxicillin-clavulinic acid was more or less similar in both bacteria. In conclusion, the resistance of Klebsiella pneumoniae and Escherichia coli isolates to B-lactams was high and this needs a strict policy for antibiotic dispensing to reduce the emergence of resistance.